Summary & Overview
HCPCS Level II S0028: Injection, Famotidine 20 mg
HCPCS Level II code S0028 denotes the parenteral administration of famotidine 20 mg. Famotidine is an H2 receptor antagonist used to reduce gastric acid secretion and is administered intravenously or intramuscularly when oral dosing is not appropriate. This code matters nationally as it captures the billing for an often-utilized acute-care medication across multiple ambulatory and inpatient settings.
Key payers considered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for famotidine injection, typical sites of service where S0028 is billed, and the practical elements that affect billing and claims processing. The publication provides benchmarks and payment context where available, summarizes relevant coverage and coding considerations, and highlights operational issues such as site-of-service designation and documentation expectations.
The report is intended for revenue cycle leaders, clinicians involved in procedural care, and policy analysts seeking a concise reference on S0028. It focuses on code definition, payer coverage landscape, billing practice considerations, and areas where additional documentation may influence reimbursement. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S0028 represents an injection of famotidine, 20 mg. This service typically denotes administration of an H2 receptor antagonist by parenteral injection for indications such as acute management of gastrointestinal acid-related conditions or peri-procedural acid suppression when oral administration is not feasible.
Service Type: Injection / Parenteral Drug Administration
Typical Site of Service: Outpatient clinic, emergency department, observation unit, or inpatient bedside administration
Clinical & Coding Specifications
Clinical Context
A patient presents to an ambulatory infusion center or emergency department with symptoms of upper gastrointestinal discomfort, suspected peptic ulcer disease, or a need for acute gastric acid suppression prior to or after endoscopic procedures. The patient may be an adult with active gastritis, reflux-related esophagitis, or who requires parenteral histamine-2 receptor antagonist therapy because they cannot tolerate or absorb oral medications. The clinical workflow typically includes nursing assessment, verification of medication orders and allergies, preparation of famotidine 20 mg for intravenous or intramuscular administration, administration by a licensed nurse or pharmacist under protocol, and monitoring for immediate adverse reactions. Documentation includes indication, route, dose (20 mg), lot number, administration time, patient tolerance, and any related procedure notes (for example, pre-endoscopy medication or treatment of stress-related mucosal bleeding). Typical site of service is an outpatient infusion center, emergency department, ambulatory surgical center, or inpatient bedside medication administration when oral route is not feasible.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when unusually extensive documentation is present because administration required substantially greater resources than typical. |